Ian Pass, Ph.D.
Ian Pass' Research Focus
Dr. Ian Pass is responsible for planning, implementing and executing HighThroughput Screening (HTS) projects within the Prebys Center at Sanford Burnham Prebys. In addition, he leads one of the three chemical biology teams, and oversees the Compound Management group at the Center. He has made contributions to the field of oncology and human disease have been far reaching and established a previously unknown potential mechanism to treat cancers. Ian has served as the primary investigator or co-investigator in all of these studies, several of which were carried out in direct collaboration with a major pharmaceutical partner. During this period he further developed his interest and skills in the early phases of drug discovery and development. Ian has practical knowledge and skills in assay development and detection technologies, laboratory automation and high-throughput screening. He has led approximately 20 HTS screening campaigns per year since 2013, collaborating with an array of both academic and industry partners. Currently, Ian leads the Center’s nuclear hormone receptor research program.
Ian Pass' Bio
For the past 20 years, Dr. Ian Pass has worked in basic research and drug discovery within several major pharmaceutical companies. Throughout this practical experience and formal education, he has acquired detailed knowledge and practical expertise in high-throughput screening, biochemical and cell-based assay development, liquid handling, assay miniaturization, laboratory automation and robotics, compound management. He also routinely leads discovery programs within the Prebys Center, leveraging his expertise in biochemistry, to drive molecules through advanced drug discovery phases.
Ian received his Ph.D. in Biochemistry at the University of Dundee, UK. Ian completed his postdoc at Sanford Burnham Preys in cancer research, and later joined the Prebys Center as a Chemical Biology Team Lead. He also directs the HTS and Compound Management group at the center.
Publications
The lipid phosphatase activity of PTEN is critical for its tumor supressor function.
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK
Proc Natl Acad Sci U S A 1998 Nov 10 ;95(23):13513-8
The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells.
Seals DF, Azucena EF Jr, Pass I, Tesfay L, Gordon R, Woodrow M, Resau JH, Courtneidge SA
Cancer Cell 2005 Feb ;7(2):155-65
Cell-Based High-Throughput Luciferase Reporter Gene Assays for Identifying and Profiling Chemical Modulators of Endoplasmic Reticulum Signaling Protein, IRE1.
Rong J, Pass I, Diaz PW, Ngo TA, Sauer M, Magnuson G, Zeng FY, Hassig CA, Jackson MR, Cosford ND, Matsuzawa S, Reed JC
J Biomol Screen 2015 Dec ;20(10):1232-45
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A, Deshpande A, Feng Y, Finlay D, Lee JS, Lazar I, Fabre B, Li Y, Fujita Y, Zhang T, Yin J, Pass I, Livneh I, Jeremias I, Burian C, Mason JR, Almog R, Horesh N, Ofran Y, Brown K, Vuori K, Jackson M, Ruppin E, Deshpande AJ, Ronai ZA
Nat Commun 2021 Sep 13 ;12(1):5397
Development of a Robust High-Throughput Screening Platform for Inhibitors of the Striatal-Enriched Tyrosine Phosphatase (STEP).
Lambert LJ, Grotegut S, Celeridad M, Gosalia P, Backer LJ, Bobkov AA, Salaniwal S, Chung TD, Zeng FY, Pass I, Lombroso PJ, Cosford ND, Tautz L
Int J Mol Sci 2021 Apr 23 ;22(9)
Serine-Threonine Kinase TAO3-Mediated Trafficking of Endosomes Containing the Invadopodia Scaffold TKS5α Promotes Cancer Invasion and Tumor Growth.
Iizuka S, Quintavalle M, Navarro JC, Gribbin KP, Ardecky RJ, Abelman MM, Ma CT, Sergienko E, Zeng FY, Pass I, Thomas GV, McWeeney SK, Hassig CA, Pinkerton AB, Courtneidge SA
Cancer Res 2021 Mar 15 ;81(6):1472-1485
Improving drug discovery using image-based multiparametric analysis of the epigenetic landscape.
Farhy C, Hariharan S, Ylanko J, Orozco L, Zeng FY, Pass I, Ugarte F, Forsberg EC, Huang CT, Andrews DW, Terskikh AV
Elife 2019 Oct 22 ;8
Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
Feng Y, Sessions EH, Zhang F, Ban F, Placencio-Hickok V, Ma CT, Zeng FY, Pass I, Terry DB, Cadwell G, Bankston LA, Liddington RC, Chung TDY, Pinkerton AB, Sergienko E, Gleave M, Bhowmick NA, Jackson MR, Cherkasov A, Ronai ZA
Cancer Lett 2019 May 1 ;449:145-162
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, Carter KP, Colayco S, Magnuson G, Brown B, Nguyen K, Vasile S, Suyama E, Smith LH, Sergienko E, Pinkerton AB, Chung TDY, Palmer AE, Pass I, Hess S, Cohen SM, Deshaies RJ
Nat Chem Biol 2017 May ;13(5):486-493
